On a day that stock market has been very bullish and ahead of a holiday on Friday on account of Mahatma Gandhi Jayanti, Equity strategist Hemang Jani, while speaking to Zee Business Managing Editor Anil Singhvi on the Special Mid-cap Picks show, revealed his top stock picks for investors to take advantage of. Jani said he was bullish on PI Industries, Tata Power and Strides Pharma. He revealed the reason why and the strategy to implement.    

COMMERCIAL BREAK
SCROLL TO CONTINUE READING

Top stocks to buy: PI Industries 

Picking PI Industries Ltd for the long-term, Jani said it is almost a debt-free company and it has a unique business model as it has tied up with global agrochemical companies and puts in a lot of effort in developing facilities in India and the company’s domestic distribution channel is also robust. Further backing his claim, Jani said the company had been generating handsome cash flow of 16-20% for the past four to five years. 

See Zee Business Live TV streaming below:

Giving a target of Rs 2350, he said PI Industries is a fine combination of domestic and global company. It has the potential to give compounded 15-20% return in long-term. PI Industries share price today ended the day on Rs 1948. Explaining the logic behind his long-term pick, the market analyst said the company has consistency, good return on equity (ROE) and is under able management. Most importantly, agri-science companies have good growth visibility in India. 

Top stocks to buy: Tata Power 

Picking Tata Power, Jani said the stock can touch Rs 70 and suggested to maintain a stop-loss of Rs 50. Jani said the promoters, who had been increasing their holding in last few years, have a keen interest in it as per all indications and this also makes it a good buy.

Watch full coverage in video below:  

Top stocks to buy: Strides Pharma  

The third stock that Jani vouched for is Strides Pharma. He said it has potential of good upside in short-term. He said Strides Pharma is a high beta company and with a good product portfolio and model, it has the potential to generate earning growth of 72% by the end of this year. Giving a short-term target of Rs 820, he said Pharma industry in general is performing well and has shown good momentum.